Establishment and characterization of a plasma cell leukaemia cell line dependent for growth on IL-6 and a bi-phenotypic subclone dependent upon both IL-3 and IL-6

Br J Haematol. 1991 Jun;78(2):217-21. doi: 10.1111/j.1365-2141.1991.tb04419.x.

Abstract

A human plasma cell leukaemia cell line (HSM-2) and a subclone (HSM-2.3) have been established from the bone marrow of a patient with bi-phenotypic leukaemia. Proliferation assays using a variety of cytokines demonstrated that HSM-2 proliferated in response to recombinant interleukin-6 (rIL-6), but did not respond to rIL-1, rIL-2, rIL-3, rIL-4, rIL-5, recombinant granulocyte-colony stimulating factor (rG-CSF), or recombinant granulocyte-macrophage-colony stimulating factor (rGM-CSF), and that HSM-2.3 responded to rIL-3 and rIL-6. HSM-2 expressed the CD38 (OKT10), PCA-1, cytoplasmic-IgM, and surface kappa light chain. HSM-2.3 expressed the CD14 (My4), CD33 (My9), CD38 (OKT10), CD19 (B4), CD24 (OKB2), CD10 (J5), PCA-1. HSM-2 and HSM-2.3 are useful tools for analysing the possible role of IL-3 and IL-6 in the oncogenesis of plasma cell leukaemia.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm / analysis
  • Antigens, Surface / analysis
  • Bone Marrow / pathology
  • Cell Division / drug effects*
  • Cell Line, Transformed
  • Clone Cells
  • Humans
  • Immunophenotyping
  • Interleukin-3 / pharmacology*
  • Interleukin-6 / pharmacology*
  • Leukemia, Plasma Cell / immunology
  • Leukemia, Plasma Cell / pathology
  • Leukemia, Plasma Cell / physiopathology*
  • Male
  • Recombinant Proteins

Substances

  • Antigens, Neoplasm
  • Antigens, Surface
  • Interleukin-3
  • Interleukin-6
  • Recombinant Proteins